Toward Heart Failure After Myocardial Infarction Cardiac S100A1 Protein Levels Determine Contractile Performance and Propensity
نویسندگان
چکیده
Andrew Remppis, Sven T. Pleger, Brent R. DeGeorge, Jr, Andrea D. Eckhart, Arthur M. Patrick Most, Hanna Seifert, Erhe Gao, Hajime Funakoshi, Mirko Völkers, Jörg Heierhorst, Toward Heart Failure After Myocardial Infarction Cardiac S100A1 Protein Levels Determine Contractile Performance and Propensity Print ISSN: 0009-7322. Online ISSN: 1524-4539 Copyright © 2006 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Circulation doi: 10.1161/CIRCULATIONAHA.106.622415 2006;114:1258-1268; originally published online September 4, 2006; Circulation. http://circ.ahajournals.org/content/114/12/1258 World Wide Web at: The online version of this article, along with updated information and services, is located on the http://circ.ahajournals.org/content/suppl/2006/08/31/CIRCULATIONAHA.106.622415.DC1.html Data Supplement (unedited) at:
منابع مشابه
Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction.
BACKGROUND Diminished cardiac S100A1 protein levels are characteristic of ischemic and dilated human cardiomyopathy. Because S100A1 has recently been identified as a Ca2+-dependent inotropic factor in the heart, this study sought to explore the pathophysiological relevance of S100A1 levels in development and progression of postischemic heart failure (HF). METHODS AND RESULTS S100A1-transgenic...
متن کاملCardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model.
As a prerequisite for clinical application, we determined the long-term therapeutic effectiveness and safety of adeno-associated virus (AAV)-S100A1 gene therapy in a preclinical large animal model of heart failure. S100A1, a positive inotropic regulator of myocardial contractility, becomes depleted in failing cardiomyocytes in humans and animals, and myocardial-targeted S100A1 gene transfer res...
متن کاملCardiac adenoviral S100A1 gene delivery rescues failing myocardium.
Cardiac-restricted overexpression of the Ca2+-binding protein S100A1 has been shown to lead to increased myocardial contractile performance in vitro and in vivo. Since decreased cardiac expression of S100A1 is a characteristic of heart failure, we tested the hypothesis that S100A1 gene transfer could restore contractile function of failing myocardium. Adenoviral S100A1 gene delivery normalized ...
متن کاملS100A1 gene therapy preserves in vivo cardiac function after myocardial infarction.
Myocardial infarction (MI) represents an enormous clinical challenge as loss of myocardium due to ischemic injury is associated with compromised left ventricular (LV) function often leading to acute cardiac decompensation or chronic heart failure. S100A1 was recently identified as a positive inotropic regulator of myocardial contractility in vitro and in vivo. Here, we explore the strategy of m...
متن کاملS100A1: A Multifaceted Therapeutic Target in Cardiovascular Disease
Cardiovascular disease is the leading cause of death worldwide, showing a dramatically growing prevalence. It is still associated with a poor clinical prognosis, indicating insufficient long-term treatment success of currently available therapeutic strategies. Investigations of the pathomechanisms underlying cardiovascular disorders uncovered the Ca(2+) binding protein S100A1 as a critical regu...
متن کامل